Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Visser, Marianne M de
PLEO-CMT-FU, NCT03023540 / 2015-002379-81: Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A	Active, not recruiting	3	187	Europe, Canada, US	PXT3003	Pharnext S.C.A., Synteract HCR (Syneos Health), Premier Research Group plc, Greenphire, Theradis, Amarex, Eurofins Optimed	Charcot-Marie-Tooth Disease, Type IA	12/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Visser, Marianne M de
PLEO-CMT-FU, NCT03023540 / 2015-002379-81: Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A	Active, not recruiting	3	187	Europe, Canada, US	PXT3003	Pharnext S.C.A., Synteract HCR (Syneos Health), Premier Research Group plc, Greenphire, Theradis, Amarex, Eurofins Optimed	Charcot-Marie-Tooth Disease, Type IA	12/24	12/24